Latest Headlines

Latest Headlines

Vaxxas scores $20M to develop needle-free vaccines

Vaxxas announced Monday that it raised $20 million in a Series B round, which will be used to advance a series of clinical programs and to develop a pipeline of new vaccine products using the company's needle-free Nanopatch platform.

Merck taps Vaxxas for Nanopatch vaccine delivery

Drug giant Merck ($MRK) will team up with Australia's Vaxxas to research the startup's drug-delivery patch that targets vaccine to immunological cells just below the skin's surface.

Start-up Vaxxas lands $16.46M for vaccine nanopatch

Australia's Vaxxas has garnered about $16.46 million in venture capital financing to support development of its Nanopatch delivery technology, which the company says could drastically change how